Literature DB >> 26002504

Bacteriophage phi11 lysin: Physicochemical characterization and comparison with phage phi80α lysin.

Lyubov Y Filatova1, David M Donovan2, Juli Foster-Frey2, Vladimir G Pugachev3, Natalia F Dmitrieva4, Tatiana A Chubar5, Natalia L Klyachko6, Alexander V Kabanov7.   

Abstract

Phage lytic enzymes are promising antimicrobial agents. Lysins of phages phi11 (LysPhi11) and phi80α (LysPhi80α) can lyse (destroy) cells of antibiotic-resistant strains of Staphylococcus aureus. Stability of enzymes is one of the parameters making their practical use possible. The objectives of the study were to investigate the stability of lysins of phages phi11 and phi80α in storage and functioning conditions, to identify optimum storage conditions and causes of inactivation. Stability of the recombinant LysPhi11 and LysPhi80α was studied using turbidimetry. CD-spectroscopy, dynamic light scattering, and electrophoresis were used to identify causes of inactivation. At 37°C, pH 7.5 and concentration of NaCl not higher than 150mM, LysPhi11 molecules contain a high percentage of random coils (43%). However, in spite of this the enzyme has high activity (0.4-0.8OD600nms(-1)mg(-1)). In storage conditions (4°C and 22°C, pH 6.0-9.0, 10-500mM NaCl) LysPhi11 is inactivated by a monomolecular mechanism. The optimum storage conditions for LysPhi11 (4°C, pH 6.0-7.5, 10mM NaCl) were selected under which the time of the enzyme half-inactivation is 120-160 days. LysPhi80α stability is insufficient: at 37°C the enzyme loses half of its activity almost immediately; at 4°C and 22°C the time of half-inactivation of LysPhi80α varies in the range from several hours to 3 days. Despite the common properties in the manifestation of antistaphylococcal activity the kinetic behavior of the enzymes is different. LysPhi11 is a more promising candidate to be used as an antimicrobial agent.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activity; Bacteriolytic enzymes; Phages; Stability; Staphylococcal infections; Structure

Mesh:

Substances:

Year:  2015        PMID: 26002504     DOI: 10.1016/j.enzmictec.2015.03.005

Source DB:  PubMed          Journal:  Enzyme Microb Technol        ISSN: 0141-0229            Impact factor:   3.493


  5 in total

Review 1.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors:  Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

2.  A light-controlled cell lysis system in bacteria.

Authors:  Geyi Wang; Xin Lu; Yisha Zhu; Wei Zhang; Jiahui Liu; Yankang Wu; Liyang Yu; Dongchang Sun; Feng Cheng
Journal:  J Ind Microbiol Biotechnol       Date:  2018-05-08       Impact factor: 3.346

3.  Development of Staphylococcus Enzybiotics: The Ph28 Gene of Staphylococcus epidermidis Phage PH15 Is a Two-Domain Endolysin.

Authors:  Magdy Mohamed Muharram; Ashraf Tawfik Abulhamd; Mohammed F Aldawsari; Mohamed Hamed Alqarni; Nikolaos E Labrou
Journal:  Antibiotics (Basel)       Date:  2020-03-30

4.  Targeting Hidden Pathogens: Cell-Penetrating Enzybiotics Eradicate Intracellular Drug-Resistant Staphylococcus aureus.

Authors:  Christian Röhrig; Markus Huemer; Dominique Lorgé; Samuel Luterbacher; Preeda Phothaworn; Christopher Schefer; Anna M Sobieraj; Léa V Zinsli; Srikanth Mairpady Shambat; Nadja Leimer; Anja P Keller; Fritz Eichenseher; Yang Shen; Sunee Korbsrisate; Annelies S Zinkernagel; Martin J Loessner; Mathias Schmelcher
Journal:  mBio       Date:  2020-04-14       Impact factor: 7.867

5.  Engineering of Long-Circulating Peptidoglycan Hydrolases Enables Efficient Treatment of Systemic Staphylococcus aureus Infection.

Authors:  Anna M Sobieraj; Markus Huemer; Léa V Zinsli; Susanne Meile; Anja P Keller; Christian Röhrig; Fritz Eichenseher; Yang Shen; Annelies S Zinkernagel; Martin J Loessner; Mathias Schmelcher
Journal:  mBio       Date:  2020-09-22       Impact factor: 7.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.